Average cumulative relative dose was found to be associated with survival over average relative dose intensity in patients with colorectal cancer, highlighting that obese patients receive lower cumulative doses of adjuvant chemotherapy and therefore may be attributed to their poorer survival outcomes.
The FDA has granted an orphan drug designation to CFT7455 for use as a potential therapeutic option in patients with multiple myeloma.
COVID-19 vaccination has been shown to induce high rates of seroconversion in patients with cancer, although those with hematologic malignancies have demonstrated lower immunogenicity and those who previously received immunosuppressive therapies appear to be less responsive.
The FDA has granted a fast track designation to IN10018 as a potential therapeutic option for use in patients with platinum-resistant ovarian cancer.
Mark D. Pegram, MD, discusses the latest data in HER2-positive metastatic breast cancer.
Sintilimab plus oxaliplatin/capecitabine significantly improved overall survival over chemotherapy alone when used as a first-line treatment in patients with unresectable, locally advanced, recurrent or metastatic gastric or gastroesophageal junction adenocarcinoma.
The FDA has issued a complete response letter to Sesen Bio regarding its biologics license application for Vicineum for the treatment of patients with Bacillus Calmette-Guérin–unresponsive non–muscle invasive bladder cancer.
Sacituzumab govitecan-hziy, a Trop-2directed antibody-drug conjugate with an SN-38 payload, has carved out a role in the treatment landscape for patients with locally advanced or metastatic urothelial cancer following accelerated approval by the FDA.
Data that emerged from the 2021 ASCO Annual Meeting represent potential paradigm shifts for patients with advanced melanoma.
One year ago, few objective observers would have suggested that the percentage of individuals who are currently fully vaccinated is less than 30%, despite the well-documented real-world success data for the vaccines in preventing serious illness, hospitalizations, and death from COVID-19 infection.
Acalabrutinib monotherapy continued to be highly active and safe in patients with relapsed/refractory mantle cell lymphoma with longer-term follow-up.
Krina K. Patel, MD, MSc, discusses the use of CAR T-cell therapy in multiple myeloma, potential target antigens beyond BCMA, the rich research landscape, and the role of quadruplets and radiation therapy.
Due to the potency of CAR T-cell therapies and the associated adverse events that can to arise in patients receiving this type of treatment, oncology nurses need to be educated on how to best identify and manage these AEs.
Stephen M. Ansell, MD, PhD, discusses recent progress made with non–CAR T-based approaches in the non-Hodgkin lymphoma treatment paradigm, opportunities for sequencing available options, and ongoing efforts that are picking up momentum.
Duvelisib monotherapy demonstrated encouraging efficacy for patients with relapsed/refractory peripheral T-cell lymphoma.
The FDA has approved belzutifan for the treatment of adult patients with von Hippel-Lindau disease who require therapy for associated renal cell carcinoma, central nervous system hemangioblastomas, or pancreatic neuroendocrine tumors that do not require immediate surgery.
The majority of patients with newly diagnosed chronic lymphocytic leukemia have better outcomes with BTK inhibitors compared with standard chemoimmunotherapy, making them the logical choice for frontline therapy.
Zandelisib plus rituximab is being evaluated as a potentially chemotherapy-free treatment strategy vs standard chemoimmunotherapy in patients with indolent non-Hodgkin lymphoma in first relapse in the ongoing, phase 3 COASTAL trial.
The United Kingdom’s National Institute for Health and Care Excellence has issued draft guidance supporting the use of abemaciclib in the treatment of adult patients with metastatic hormone receptor–positive/HER2-negative breast cancer.
Zanubrutinib demonstrated clinical activity and tolerability in previously treated patients with B-cell malignancies who were intolerant to therapy with ibrutinib and/or acalabrutinib, according to results of the phase 2 BGB-3111-215 trial.
The FDA has granted a breakthrough therapy designation to toripalimab for single-agent use in combination with gemcitabine and cisplatin in the frontline treatment of patients with recurrent or metastatic nasopharyngeal carcinoma.
Jean-Jacques Kiladjian, MD, PhD, discusses the effectiveness of momelotinib compared with ruxolitinib in patients with myelofibrosis who have anemia and are naïve to JAK inhibitors.
As more CAR T-cell therapies are approved for the treatment of patients with hematologic malignancies, adopting management strategies for cytokine release syndrome and immune effector cell–associated neurotoxicity syndrome using newly standardized grading criteria is an important component of utilizing these products in practice.
Maintenance niraparib has been shown to result in a significant progression-free survival benefit in patients with BRCA-mutated ovarian cancer following response to platinum-based chemotherapy.
The widening treatment paradigm for various breast cancer subtypes is yielding improved survival with more tailored strategies.
